Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
about
Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone TreatmentAndrogen Receptor Signaling in Salivary Gland Cancer.Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.Developing Androgen Receptor Targeting for Salivary Gland Cancers.
P2860
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Activity of abiraterone in rec ...... androgen-deprivation therapy.
@en
type
label
Activity of abiraterone in rec ...... androgen-deprivation therapy.
@en
prefLabel
Activity of abiraterone in rec ...... androgen-deprivation therapy.
@en
P2093
P2860
P50
P356
P1476
Activity of abiraterone in rec ...... o androgen-deprivation therapy
@en
P2093
Barbara Cortelazzi
Gaetana Rinaldi
Silvana Pilotti
P2860
P304
P356
10.4161/CBT.28410
P50
P577
2014-03-11T00:00:00Z